Nextech Venture

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.

MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's portfolio includes several investigational products, such as Margetuximab, a monoclonal antibody in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other candidates in development include MGA012 and MGD013, both targeting PD-1, as well as MGD019, which targets multiple immune checkpoints. MacroGenics is also advancing MGC018, an antibody-drug conjugate targeting B7-H3, and MGD014, a DART molecule designed for HIV-infected cells. The company has formed strategic collaborations with several organizations to enhance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics for cancer and other related diseases.

ImVisioN Therapeutics is pioneering ILIT, a proprietary technology for the delivery of immunotherapy in the treatment of allergies. ILIT is clinically proven and has been shown to be a safer, more effective means of delivering allergy therapeutics. By applying another technology called modular antigen transporter (MAT), ImVisioN leverages the potential of ILIT to develop drugs that use allergens safely for specific and highly effective antigen presentation. In addition to the company’s lead product for the treatment of cat dander allergy, it also has programs addressing birch pollen and house dust mite allergies.